Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disease
characterized by a permanent degeneration of both upper and lower motor neurons. Many …

Importance Intravenous edaravone is approved as a disease-modifying drug for patients
with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term …

Inflammation is a shared hallmark between amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTD). For long, studies were conducted on tissues of post-mortem …

Importance Using real-world data, the US Department of Veterans Affairs (VA) initiated a
surveillance evaluation of edaravone after its approval for amyotrophic lateral sclerosis …

There are trillions of different microorganisms in the human digestive system. These gut
microbes are involved in the digestion of food and its conversion into the nutrients required …

Radicava™(Edaravone) was approved the Food and Drug Administration (FDA) as a new
treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that …

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that
affects the upper and lower motor neurons. Currently, the only treatment for ALS is riluzole …

Introduction To date, riluzole and edaravone are the only two drugs that have successfully
passed clinical trials for the treatment of Amyotrophic Lateral Sclerosis (ALS). Unfortunately …

Background Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neuromuscular
disease with no curative therapies. Edaravone (Radicava®)(Mitsubishi Tanabe Pharma …

Amyotrophic lateral sclerosis (ALS) leads to death within 2–5 yr. Currently, available drugs
only slightly prolong survival. We present novel insights into the pathophysiology of …